Other News To Note

 The ALS Therapy Development Institute entered a research agreement with Biogen Idec Inc., of Cambridge, Mass., and UCB Pharma SA, of Brussels, Belgium, to investigate the use of an anti-CD40L antibody as a potential therapy for amyotrophic lateral sclerosis (ALS).